Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors
The DOI matches its Crossref record.
Abstract
Background: There is a growing appreciation for the GM in response to melanoma therapy. Recent work identified a favorable (T1) GM signature associated with checkpoint benefit. However, little is known about how lifestyle factors may influence features of the GM or about the influence of the GM on therapeutic outcomes to other common melanoma therapies. Methods: We prospectively collected fecal samples melanoma patients at MD Anderson Cancer Center and characterized the GM via 16S rRNA sequencing (n=146). In a subset initiating systemic therapy (n= 113), we also collected baseline diet information via the NCI dietary screener questionnaire, and probiotic and antibiotic use and followed for response (RECISTv1.1). We compared GM beta diversity (BD)(Bray-Curtis) with ANOSIM and descriptive statistics and Wilcoxon tests were applied to alpha diversity (AD)(Chao1) among treatment response groups. Spearman correlation was used to test relationships of dietary groups and GM composition. Univariate and multivariate logistic regression models were used to determine the individual and joint effects of lifestyle factors on response. Receiver operating characteristic (ROC) curves were constructed for area under the curve (AUC) quantification. Results: Considering all treatment groups, baseline AD was highest in patients with complete/partial response (mean=355), compared to patients with stable (mean=330) and progressive disease (mean=318). The GM did not significantly differ by age, sex or BMI. Report of probiotic (42%) and antibiotic (29%) use at baseline was associated with lower AD (p=0.02). Whole grains and overall diet quality correlated positively with pro-response bacteria, added sugars and processed meat negatively correlated. GM community structure (BD) differed by high and low fiber intake (p<0.05). Patients with high vs. low fiber diet had higher odds of response to aPD1 (OR=5.3, 95% CI: 1.02-26.3) and AUC for fiber in predicting response was 0.65. Joint effects analysis showed greatest odds of response among patients with a T1 signature and high fiber diet (OR=3.6, 95% CI: 0.7-17.8) vs. low fiber diet (OR=1.9, 95%CI 0.6-6.4), compared to patients without a T1 signature. Similar results were seen for overall diet score; and for both fiber and diet score, results reached statistical significance excluding patients on antibiotics. Conclusion: AD of the GM varies by response regardless of treatment type. While preliminary, this data points to the idea that the GM in melanoma patients may be negatively influenced by probiotics and could be targeted by dietary manipulation. Larger prospective and interventional studies are needed to assess the relationships between host lifestyle factors, the GM and response to melanoma therapies. Citation Format: Christine N. Spencer, Vancheswaran Gopalakrishnan, Jennifer McQuade, Miles C. Andrews, Beth Helmink, M.A. Wadud Khan, Elizabeth Sirmans, Lauren Haydu, Alexandria Cogdill, Elizabeth Burton, Rodabe Amaria, Sapna Patel, Isabella Glitza, MIchael Davies, Eliza Posada, Wen-Jen Hwu, Adi Diab, Kelly Nelson, Hussein Tawbi, Michael Wong, Robert R. Jenq, Lorenzo Cohen, Carrie Daniel-MacDougall, Jennifer A. Wargo. The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2838.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Matson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
Di Modica, M., Gargari, G., Regondi, V., Bonizzi, A., Arioli, S., Belmonte, B., De Cecco, L., Fasano, E., Bianchi, F., Bertolotti, A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1659 · Cited by 184
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Metadata
- Authors
- Spencer, C. N., Gopalakrishnan, V., McQuade, J., Andrews, M. C., Helmink, B., Khan, M. A. W., Sirmans, E., Haydu, L., Cogdill, A., Burton, E., Amaria, R., Patel, S., Glitza, I., Davies, M., Posada, E., Hwu, W.-J., Diab, A., Nelson, K., Tawbi, H., Wong, M., Jenq, R. R., Cohen, L., Daniel-MacDougall, C., & Wargo, J. A.
- Venue
- Cancer Research
- Published
- 2019-07-01
- Volume
- 79
- Issue
- 13_Supplement
- Pages
- 2838-2838
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2954998528
- Cited by
- 60
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. https://app.cochat.ai/papers/10.1158/1538-7445.am2019-2838
- The paper
- Spencer, C. N., Gopalakrishnan, V., McQuade, J., Andrews, M. C., Helmink, B., Khan, M. A. W., Sirmans, E., Haydu, L., Cogdill, A., Burton, E., Amaria, R., Patel, S., Glitza, I., Davies, M., Posada, E., Hwu, W.-J., Diab, A., Nelson, K., Tawbi, H., . . . Wargo, J. A. (2019). Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. Cancer Research. https://doi.org/10.1158/1538-7445.am2019-2838
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.